GSK may shift some Relenza manufacturing to mainland

SHANGHAI: British drugmaker GlaxoSmithKline (GSK) Plc is planning to move part of its flu drug Relenza manufacture to China to better support the local market.

"I hope that we will be able to shift some Relenza manufacture to China to make our products more accessible in the country," said Chief Executive Andrew Witty.

The drug, which received the State Food and Drug Administration (SFDA) approval in September for domestic sales, is used to fight the flu virus along with Roche's Tamiflu.